Zhongzhi Pharmaceutical Holdings (HKSE:03737) Research & Development: HK$0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03737 Zhongzhi Pharmaceutical Holdings Ltd HKSE:03737
47 GF Score
Price HK$0.71
GF Value HK$0.89
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Zhongzhi Pharmaceutical Holdings Research & Development?

Zhongzhi Pharmaceutical Holdings HKSE:03737 47 Research & Development is HK$0 Mil as of Dec. 2025. GuruFocus rates HKSE:03737 with a GF Score™ of 47/100 and a GF Value™ of HK$0.89 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Zhongzhi Pharmaceutical Holdings's Research & Development for the six months ended in Dec. 2025 was HK$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0 Mil.

Zhongzhi Pharmaceutical Holdings  (HKSE:03737) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Zhongzhi Pharmaceutical Holdings Research & Development Related Terms

Zhongzhi Pharmaceutical Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Zhongzhi Pharmaceutical Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhongzhi Pharmaceutical Holdings Research & Development Chart

Zhongzhi Pharmaceutical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.67 51.76 54.67 60.87 45.80

Zhongzhi Pharmaceutical Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:03737
47GF Score
Zhongzhi Pharmaceutical Holdings Ltd HKSE:03737
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhongzhi Pharmaceutical Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$0 Mil mean?
Zhongzhi Pharmaceutical Holdings (HKSE:03737) has a Research & Development of HK$0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Zhongzhi Pharmaceutical Holdings and its competitors.
Is Zhongzhi Pharmaceutical Holdings' Research & Development too high?
Zhongzhi Pharmaceutical Holdings' current Research & Development is HK$0 Mil. Overall, Zhongzhi Pharmaceutical Holdings has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhongzhi Pharmaceutical Holdings' Research & Development compare to ZTS?
Zhongzhi Pharmaceutical Holdings' Research & Development of HK$0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Zhongzhi Pharmaceutical Holdings and its competitors. Zhongzhi Pharmaceutical Holdings's current Research & Development is HK$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongzhi Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zhongzhi Pharmaceutical Holdings (HKSE:03737) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.89, compared to a current price of HK$0.71 — trading 20.2% below its estimated fair value. The current Research & Development is HK$0 Mil. Zhongzhi Pharmaceutical Holdings' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Zhongzhi Pharmaceutical Holdings (HKSE:03737), the current Research & Development is HK$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhongzhi Pharmaceutical Holdings (HKSE:03737) Overvalued in 2026?

Based on GuruFocus' analysis, Zhongzhi Pharmaceutical Holdings stock appears to be undervalued. The current stock price of HK$0.71 is trading 20.2% below its estimated GF Value™ of HK$0.89. GuruFocus considers Zhongzhi Pharmaceutical Holdings to be Modestly Undervalued.

Key valuation signals for HKSE:03737:

  • Research & Development: HK$0 Mil
  • GF Value™: HK$0.89 vs. price of HK$0.71 (20.2% below fair value)
  • GF Score™: 47/100 with 7 warning signs

No single metric tells the full story. See the HKSE:03737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhongzhi Pharmaceutical Holdings Business Description

Address No. 3 Kangtai Road South, Torch Development Zone, Guangdong Province, Zhongshan, CHN
Zhongzhi Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceutical products in the PRC. The Group is a large industrial and trading enterprise group featuring researching, producing, and selling traditional Chinese medicine preparations, prepared slices of Chinese crude drugs, and foods. Its products include Shenqi Koufuye, Yinhuang Jiaonang, Yinhuang Keli, and others. Its segments are the pharmaceutical manufacturing segment, which generates maximum revenue, is engaged in the research and development, manufacturing, and sale of Chinese patent medicines and decoction pieces consisting of traditional decoction pieces and modern decoction pieces, and the operation of the chain pharmacies segment.
47GF Score

Get the complete analysis for HKSE:03737

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.71
Price
HK$0.89
GF Value